From a life-cycle perspective to RWE and patient-centered HTA
The Deree – School of Graduate and Professional Education, in collaboration with the Hellenic Society of Pharmaceutical Medicine – EL.E.F.I and the International Federation of Associations IFAPP of Pharmaceutical Medicine and Pharmaceutical Physicians are pleased to announce a new course on Pharmaceutical Medicine, “Current Trends in Health Technology Assessment: From a life-cycle perspective to RWE and patient-centered HTA.”
Classes start:
November 1, 2024
When: November 1, 2, 8 & 9, 2024 / Fridays and Saturdays, 10:00-16:00
Where: Deree – The American College of Greece, Aghia Paraskevi Campus (6 Gravias Str, 153 42 Aghia Paraskevi)
Language of Instruction: English
Audience: By registration only
Overview
Current trends in Health Technology Assessment (HTA) are expected to shape its future. Taking a life cycle perspective from development to post-marketing and divestment creates a new concept. Increasing the use of real-world evidence (RWE) in HTA by providing a wider range of evidence would lead to a new standard. Public and patient involvement in HTA signals a new and important patient-centered pathway.
Who is this for?
The course is suitable for R&D professionals, Market Access, Patient Access, Patient Safety-Pharmacovigilance, Regulatory affairs, Business units, Medical Affairs, Governmental & Public Affairs teams, professionals in Academia, Health Economists, Health Policy Scientists and Health Care professionals, Pharmaceutical Industry, Medical Devices Industry and Clinical Research Organizations CROs.
Why attend?
The anticipated benefits and objectives include:
- The importance of HTA for equitable and efficient health systems that meet the needs of society in line with current scientific developments, including precision medicine and advanced therapies.
- Understand the requirements for research design and methodology in line with international best practices for evidence and the new European HTA Regulation (HTAR).
- Identify challenges in selecting appropriate research designs for HTA.
- Identify needs and prepare organizations and institutions for HTA.
- Ensure a successful outcome of HTA for the benefit of patients.
Learning Outcomes
Upon completion of the course, participants will be able to:
- Learn to plan and conduct appropriate HTAR in practice.
- Anticipate challenges and design appropriate studies to generate the evidence needed.
- Improve the quality, relevance and acceptability of evidence for patient care.
Dates & times
4 meetings – 24 contact hours in total
Time:
10:00-16:00
Dates:
Friday, November 1, 2024
Saturday, November 2, 2024
Friday, November 8, 2024
Saturday, November 9, 2024
To download the detailed schedule, please click here.
Certificate of Participation
In order to be awarded the Certificate of Participation from the Deree – School of Graduate and Professional Education, participants need to attend 20 out of 24 hours and achieve an 80% pass on the final assessment.
Course fees
Regular single participant fee: €600
Members of the ACG community and members of the Hellenic Society of Pharmaceutical Medicine (EL.E.F.I. & IFAPP): €400
Group of 3-4: 10% discount
Group of 5-10: 15% discount
Group of 11+: 20% discount
About the Hellenic Society of Pharmaceutical Medicine – EL.E.F.I.
The Hellenic Society of Pharmaceutical Medicine – EL.E.F.I., is a non-profit scientific society, established in 1991 in Athens, that aims to advance the field of Pharmaceutical Medicine through the following set of goals:
- Advance the collective scientific activity within the pharmaceutical industry landscape, primarily focusing on clinical research, pharmacovigilance and regulatory issues related to medicines development and approval.
- Facilitate and support the scientific and professional development of its members.
- Develop and foster scientific interactions and collaborations with Healthcare Institutions, international organizations and scientific associations in Greece and abroad.
- Organize one-day educational events, Symposia and Congresses.
- Foster active representation in scientific associations and institutions with related interests in Greece and abroad.
About the International Federation of Associations of Pharmaceutical Medicine and Pharmaceutical Physicians – IFAPP
IFAPP is a non-profit global scientific organization registered in the Netherlands under registration number 30224375. The foundations of IFAPP were laid in 1970 by three British Pharmaceutical Physicians, Bill Burland, Jan Jouhar and Richard Rondel. IFAPP is comprised of the leading professional associations in the fields of Pharmaceutical Medicine and medicines development. These National Member Associations (NMAs) pay dues to support IFAPP’s work and guide its efforts by participating in its working groups and naming representatives to IFAPP’s House of Delegates.
The mission of the Federation is to advance Pharmaceutical Medicine by enhancing the knowledge, expertise and skills of pharmaceutical physicians and other professionals involved in all scientific disciplines addressing the discovery, development, processing and usage of medicines as well as experimental and clinical research worldwide, leading to the availability and appropriate use of medicines for the benefit of patients and society.
IFAPP works closely with the following international organizations: the PharmaTrain, Mastering Medicines Development in Europe, the ECPM, European Centre for Pharmaceutical Medicine, the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians in the UK, the Trinity College Dublin, University of Dublin, the Gesellschaft für Pharmazeutische Medizin (GPMED) in Austria, the Hellenic Society of Pharmaceutical Medicine (EL.E.F.I.), the World Medical Association, the Council for International Organizations of Medical Sciences, CIOMS established jointly by WHO and UNESCO. IFAPP follows closely with the European Medicines Agency (EMA), the Federal Drugs Administration (FDA), the Japanese Regulatory Pharmaceuticals and Medical Devices Agency(PMDA) and the World Health Organization (WHO).
Instructors
President IFAPP
With over 35 years of experience as Consultant in Internal Medicine, and Pharmaceutical Medicine Expert, Varvara Baroutsou led Research & Development practice where she focused on improving medicines development, translational research, clinical trial operations and evidence generation for innovative treatments. She has started her career as a Hospital Physician & Clinical Investigator and then moved on t osenior leadership roles in Clinical Development and Medical Affairs of several large pharmaceutical and biotechnology companies in Europe. Currently she is affiliated with not-for-profit scientific organisations, academia, patients’ associations, and multinational organisations to implement complex change management initiatives to pursue excellence in clinical research, patient engagement and responsible ethical conduct with her latest role being President of International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine (IFAPP). Varvara’s academic records include scientific journal reviewer and editor experience, publications, book chapters and advisory contributions to educational, technical, and regulatory standards committees. She is a Doctor of Medicine from the University of Athens, Greece, a licensed certified Consultant, a Global Fellow in Medicines Development with a postgraduate degree in Health Economics, from Stockholm School of Economics and a European Market Access Diploma from the University of Lyon.
Eugena Stamuli is a Health Economist (MSc, University of Sheffield, UK) with first degree in Pharmacy (BSc, National University of Athens, Greece). Her areas of expertise include cost-effectiveness modelling/early modelling for health technology assessment, design and conduct of economic evaluations alongside clinical trials, discrete choice experiments (DCEs), patient reported outcomes (PROs), utility elicitation and evidence review & synthesis. She has conducted numerous primary studies and analyses in various disease areas. Eugena is Director of HESCHOICES, an international consulting company in Health Economics, Outcomes Research and Market Access. She holds a Visiting Research Fellowship position with University of York, UK where she worked for nearly 10 years as an academic researcher.
For more information, please email [email protected] or call +30 210 600 9800 ext. 1532, 1332.
Classes start: November 1, 2024
Online Registration Form